Institutional members access full text with Ovid®

Share this article on:

BMI history and risk of incident fatty liver: a population-based large-scale cohort study

Hashimoto, Yoshitaka; Hamaguchi, Masahide; Fukuda, Takuya; Nakamura, Naoto; Ohbora, Akihiro; Kojima, Takao; Fukui, Michiaki

European Journal of Gastroenterology & Hepatology: October 2016 - Volume 28 - Issue 10 - p 1188–1193
doi: 10.1097/MEG.0000000000000682
Original Articles: Metabolic Liver Diseases

Background and aims Most physicians might consider that fatty liver would develop along with increasing body weight; however, an association between BMI history and incident fatty liver has not been clarified as yet.

Methods We carried out a population-based cohort study that included 4427 healthy Japanese individuals who received yearly health-checkup programs over a decade. Fatty liver was diagnosed using ultrasonography.

Results During the observational period, 38.7% (case/N=1002/2588) of men and 17.3% (319/1847) of women were diagnosed with fatty liver. Among these, only 18.9% (189 of 1002 participants) of men and 18.5% (59 of 319) of women developed fatty liver when they reached the lifetime maximum BMI. Adjusted odds ratio of the difference between lifetime maximum BMI and BMI at age 20 years (ΔBMImax−20 years) for incident fatty liver was 1.33 [95% confidence interval (CI) 1.28–1.39, P<0.001] in men or 1.40 (95% CI 1.33–1.49, P<0.001) in women. According to receiver operator characteristic (ROC) analysis, the optimal cut-off points of ΔBMImax−20 years for incident fatty liver were 4.82 kg/m2 [area under ROC curve 0.70 (95% CI 0.68–0.72), P<0.001] in men and 4.11 kg/m2 [area under ROC curve 0.76 (95% CI 0.73–0.79), P<0.001] in women.

Conclusion The ΔBMImax−20 years was associated with an increased risk of incident fatty liver. In addition, more patients developed fatty liver not at the maximum point of BMI history, but after that. Therefore, it is useful to check ΔBMImax−20 years and to continue observing the individuals for detection of fatty liver.

aDepartment of Endocrinology and Metabolism, Graduate School of Medical Science, Kyoto Prefectural University of Medicine

bDepartment of Diabetology, Kameoka Municipal Hospital, Kyoto

cDepartment of Gastroenterology, Murakami Memorial Hospital, Asahi University, Gifu, Japan

Correspondence to Masahide Hamaguchi, MD, PhD, Department of Diabetology, Kameoka Municipal Hospital, 1-1 Noda, Shinochoshino, Kameoka-city, Kyoto 621-8585, Japan Tel: +81 771 25 7313; fax: +81 771 25 7312; e-mail: seele@koto.kpu-m.ac.jp

Received February 9, 2016

Accepted May 9, 2016

Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved.